Attention-deficit-hyperactivity disorder and reward deficiency syndrome

Kenneth Blum1,6,7,8,9,10, Amanda Lih-Chuan Chen2, Eric R Braverman3,9, David E Comings4, Thomas JH Chen5, Vanessa Arcuri9, Seth H Blum6, Bernard W Downs7,8, Roger L Waite7, Alison Notaro9, Joel Lubar10, Lonna Williams7, Thomas J Prihoda11, Tomas Palomo12, Marlene Oscar-Berman131Department of Physiol...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kenneth Blum, Amanda Lih-Chuan Chen, Eric R Braverman, David E Comings, Thomas JH Chen, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/a14ae1fe19b34d04902127feff2b6efc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a14ae1fe19b34d04902127feff2b6efc
record_format	dspace
spelling	oai:doaj.org-article:a14ae1fe19b34d04902127feff2b6efc2021-12-02T05:18:15ZAttention-deficit-hyperactivity disorder and reward deficiency syndrome1176-63281178-2021https://doaj.org/article/a14ae1fe19b34d04902127feff2b6efc2008-11-01T00:00:00Zhttp://www.dovepress.com/attention-deficit-hyperactivity-disorder-and-reward-deficiency-syndrom-a2557https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Kenneth Blum1,6,7,8,9,10, Amanda Lih-Chuan Chen2, Eric R Braverman3,9, David E Comings4, Thomas JH Chen5, Vanessa Arcuri9, Seth H Blum6, Bernard W Downs7,8, Roger L Waite7, Alison Notaro9, Joel Lubar10, Lonna Williams7, Thomas J Prihoda11, Tomas Palomo12, Marlene Oscar-Berman131Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, NC; 2Department of Engineering and Management of Advanced Technology, Chang Jung University, Tainan, Taiwan, Republic of China; 3Department of Neurosurgery, Weill College of Medicine, New York, NY; 4Department of Medical Genetics, City of Hope Medical Center, Duarte, CA; 5Department of Occupational Safety and Health, Chang Jung University, Tainan, Taiwan, Republic of China; 6Department of Psychoneurogenetics, Synapatamine, Inc., San Antonio, TX; 7LifeGen, Inc., La Jolla, CA; 8Allied Nutraceutical Research, Lederach, PA; 9PATH Research Foundation, New York, NY; 10Department of Physiology, University of Tennessee, Knoxville, TN; 11Department of Pathology, University of Texas Health Science Center, San Antonio, TX; 12Hospital Universitario 12 de Octubre, Madrid, Spain; 13Boston University School of Medicine, and Boston VA Healthcare System, Boston, MAParts of this manuscript have been published in Theor Biol Med Model (Comings et al 2005), which is an open access journalAbstract: Molecular genetic studies have identified several genes that may mediate susceptibility to attention deficit hyperactivity disorder (ADHD). A consensus of the literature suggests that when there is a dysfunction in the &ldquo;brain reward cascade,&rdquo; especially in the dopamine system, causing a low or hypo-dopaminergic trait, the brain may require dopamine for individuals to avoid unpleasant feelings. This high-risk genetic trait leads to multiple drug-seeking behaviors, because the drugs activate release of dopamine, which can diminish abnormal cravings. Moreover, this genetic trait is due in part to a form of a gene (DRD2 A1 allele) that prevents the expression of the normal laying down of dopamine receptors in brain reward sites. This gene, and others involved in neurophysiological processing of specific neurotransmitters, have been associated with defi cient functions and predispose individuals to have a high risk for addictive, impulsive, and compulsive behavioral propensities. It has been proposed that genetic variants of dopaminergic genes and other &ldquo;reward genes&rdquo; are important common determinants of reward deficiency syndrome (RDS), which we hypothesize includes ADHD as a behavioral subtype. We further hypothesize that early diagnosis through genetic polymorphic identification in combination with DNA-based customized nutraceutical administration to young children may attenuate behavioral symptoms associated with ADHD. Moreover, it is concluded that dopamine and serotonin releasers might be useful therapeutic adjuncts for the treatment of other RDS behavioral subtypes, including addictions.Keywords: attention deficit hyperactivity disorder (ADHD), genes, reward dependence, reward deficiency syndrome, treatment, neuropsychological deficits Kenneth BlumAmanda Lih-Chuan ChenEric R BravermanDavid E ComingsThomas JH Chenet alDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2008, Iss Issue 5, Pp 893-917 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Kenneth Blum Amanda Lih-Chuan Chen Eric R Braverman David E Comings Thomas JH Chen et al Attention-deficit-hyperactivity disorder and reward deficiency syndrome
description	Kenneth Blum1,6,7,8,9,10, Amanda Lih-Chuan Chen2, Eric R Braverman3,9, David E Comings4, Thomas JH Chen5, Vanessa Arcuri9, Seth H Blum6, Bernard W Downs7,8, Roger L Waite7, Alison Notaro9, Joel Lubar10, Lonna Williams7, Thomas J Prihoda11, Tomas Palomo12, Marlene Oscar-Berman131Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, NC; 2Department of Engineering and Management of Advanced Technology, Chang Jung University, Tainan, Taiwan, Republic of China; 3Department of Neurosurgery, Weill College of Medicine, New York, NY; 4Department of Medical Genetics, City of Hope Medical Center, Duarte, CA; 5Department of Occupational Safety and Health, Chang Jung University, Tainan, Taiwan, Republic of China; 6Department of Psychoneurogenetics, Synapatamine, Inc., San Antonio, TX; 7LifeGen, Inc., La Jolla, CA; 8Allied Nutraceutical Research, Lederach, PA; 9PATH Research Foundation, New York, NY; 10Department of Physiology, University of Tennessee, Knoxville, TN; 11Department of Pathology, University of Texas Health Science Center, San Antonio, TX; 12Hospital Universitario 12 de Octubre, Madrid, Spain; 13Boston University School of Medicine, and Boston VA Healthcare System, Boston, MAParts of this manuscript have been published in Theor Biol Med Model (Comings et al 2005), which is an open access journalAbstract: Molecular genetic studies have identified several genes that may mediate susceptibility to attention deficit hyperactivity disorder (ADHD). A consensus of the literature suggests that when there is a dysfunction in the &ldquo;brain reward cascade,&rdquo; especially in the dopamine system, causing a low or hypo-dopaminergic trait, the brain may require dopamine for individuals to avoid unpleasant feelings. This high-risk genetic trait leads to multiple drug-seeking behaviors, because the drugs activate release of dopamine, which can diminish abnormal cravings. Moreover, this genetic trait is due in part to a form of a gene (DRD2 A1 allele) that prevents the expression of the normal laying down of dopamine receptors in brain reward sites. This gene, and others involved in neurophysiological processing of specific neurotransmitters, have been associated with defi cient functions and predispose individuals to have a high risk for addictive, impulsive, and compulsive behavioral propensities. It has been proposed that genetic variants of dopaminergic genes and other &ldquo;reward genes&rdquo; are important common determinants of reward deficiency syndrome (RDS), which we hypothesize includes ADHD as a behavioral subtype. We further hypothesize that early diagnosis through genetic polymorphic identification in combination with DNA-based customized nutraceutical administration to young children may attenuate behavioral symptoms associated with ADHD. Moreover, it is concluded that dopamine and serotonin releasers might be useful therapeutic adjuncts for the treatment of other RDS behavioral subtypes, including addictions.Keywords: attention deficit hyperactivity disorder (ADHD), genes, reward dependence, reward deficiency syndrome, treatment, neuropsychological deficits
format	article
author	Kenneth Blum Amanda Lih-Chuan Chen Eric R Braverman David E Comings Thomas JH Chen et al
author_facet	Kenneth Blum Amanda Lih-Chuan Chen Eric R Braverman David E Comings Thomas JH Chen et al
author_sort	Kenneth Blum
title	Attention-deficit-hyperactivity disorder and reward deficiency syndrome
title_short	Attention-deficit-hyperactivity disorder and reward deficiency syndrome
title_full	Attention-deficit-hyperactivity disorder and reward deficiency syndrome
title_fullStr	Attention-deficit-hyperactivity disorder and reward deficiency syndrome
title_full_unstemmed	Attention-deficit-hyperactivity disorder and reward deficiency syndrome
title_sort	attention-deficit-hyperactivity disorder and reward deficiency syndrome
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/a14ae1fe19b34d04902127feff2b6efc
work_keys_str_mv	AT kennethblum attentiondeficithyperactivitydisorderandrewarddeficiencysyndrome AT amandalihchuanchen attentiondeficithyperactivitydisorderandrewarddeficiencysyndrome AT ericrbraverman attentiondeficithyperactivitydisorderandrewarddeficiencysyndrome AT davidecomings attentiondeficithyperactivitydisorderandrewarddeficiencysyndrome AT thomasjhchen attentiondeficithyperactivitydisorderandrewarddeficiencysyndrome AT etal attentiondeficithyperactivitydisorderandrewarddeficiencysyndrome
_version_	1718400487186759680

Attention-deficit-hyperactivity disorder and reward deficiency syndrome

Ejemplares similares